Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tavapadon PK in severe renal impairment
NCT05404542Phase 1Completed
- Sponsor
- Cerevel Therapeutics
- Start
- May 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tavapadon in Parkinson's disease (PD) (2 arms), sponsored by Cerevel Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration at Day 7, Area Under the Plasma Concentration-time Curve from Time Zero to Time t at Day 7 and 1 more. Started May 2022; status: completed.
02
Drugs
tavapadon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05404542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05404542.